Owlstone Medical named as one of FierceMedTech’s “Fierce 15” companies of 2019
Published on: 9 Mar 2020
Cambridge, UK, March 9 2020 – Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced that it has been named by FierceMedTech as one of 2019’s Fierce 15. The Fierce 15 celebrates the spirit of being “fierce”, championing innovation and creativity, even in the face of intense competition, designating Owlstone Medical as one of the most promising private medtech companies in the industry.
Owlstone Medical’s goal is to realize the enormous healthcare and economic promise of breath-based diagnostics through the development and application of Breath Biopsy, which operates by detecting volatile organic compounds (VOCs) produced as the end product of metabolic processes within the body or as a result of chemicals from external sources.
Breath Biopsy is being deployed through paid-for biomarker discovery programs with large pharmaceutical partners such as AstraZeneca and GlaxoSmithKline, as well as with leading academic institutions, and through the development of high value diagnostic tests in areas including cancer, liver disease, and respiratory disease.
Last year, the Company added Johnson & Johnson to its ever-broadening list of pharma and academic clients, entered into a partnership with Thermo Fisher Scientific to support breath-based biomarker discovery, and joined major EU-funded research consortia investigating immune disease (3TR) and workplace exposure (EPHOR).
Billy Boyle, co-founder and CEO at Owlstone Medical, said: “Being recognized as one of the Fierce 15 is a fantastic endorsement of Breath Biopsy and its potential to transform early disease detection and the delivery of precision medicine, and we would like to thank FierceMedTech for including Owlstone Medical in this prestigious list. This comes following a year of successes that have considerably advanced breath-based diagnostics, and we are excited to build on this momentum in 2020.”
“One of the true joys of covering this field is being able to talk with the people driving the next great medical advancements—technologies that may not just change a patient or parent’s life, but also the day-to-day work of clinicians, surgeons, researchers and developers themselves,” said Conor Hale, associate editor of FierceMedTech. “Potential breakthroughs such as these can ripple into new therapies, procedures and interventions, and ultimately more ways to heal more people.”
An internationally recognized daily report reaching a network of over 90,000 medtech industry professionals, FierceMedTech provides subscribers with an authoritative analysis of the day’s top stories. Every year FierceMedTech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and competitive market position.
This is FierceMedTech’s 8th annual Fierce 15 selection, this year’s full list can be viewed at:
https://www.fiercebiotech.com/special-report/fiercemedtech-s-2019-fierce-15
The Fierce 15 profile of Owlstone Medical can be found here:
https://www.fiercebiotech.com/special-report/owlstone-medical-fiercemedtech-2019-fierce-15
ENDS
For more information on Owlstone Medical please contact:
Sarah Jeffery, Zyme Communications
sarah.jeffery@zymecommunications.com
+44 (0) 7771-730919
For more information on FierceMedTech please contact:
Rebecca Willumson, Questex, FierceMedTech
202-824-5050
About Owlstone Medical (www.owlstonemedical.com):
Owlstone Medical’s vision is to save 100,000 lives and $1.5 billion in healthcare costs by realizing the enormous promise of breath-based diagnostics through the development and application of Breath Biopsy®. Breath Biopsy operates by detecting volatile organic compounds (VOCs) produced as the end product of metabolic processes within the body or as a result of chemicals from external sources such as diet or medication, changes in which can be characteristic of specific disease or indicate environmental exposure.
The Breath Biopsy platform includes ReCIVA®, a proprietary sample collection device that can take stable breath samples anywhere, the world’s only commercial Breath Biopsy Laboratory located in Cambridge, UK, and the development of the world’s largest Digital Breath Biobank matched to patient phenotype.
Owlstone Medical is deploying the platform to address some of the key challenges of 21st century healthcare. The focus is on the early detection of disease with an emphasis on cancer, with clinical trials underway to develop breath tests for the early detection of lung and colorectal cancer, and on precision medicine through partnerships with large pharmaceutical companies including AstraZeneca, Actelion Pharmaceuticals (a J&J company), and GlaxoSmithKline to enable therapeutics to be deployed more effectively. Owlstone Medical’s technology is currently in use at over 100 sites worldwide.
About FierceMedTech (www.fiercebiotech.com/medtech):
FierceMedTech keeps biopharma executives, device developers, engineers, and researchers updated on the must-know news, trends and developments in medical technology. More than 90,000 top industry professionals rely on FierceMedTech for an insider briefing on the day’s top stories.
About Questex (www.questex.com):
Questex helps people live better and longer. Questex brings people together in the markets that help people live better: travel, hospitality and wellness; the industries that help people live longer: life science and healthcare; and the technologies that enable and fuel these new experiences. We live in the experience economy—connecting our ecosystem through live events, surrounded by data insights and digital communities. We deliver experience and real results. It happens here.
